PX-12 is well tolerated in solid tumors, and with our preclinical rationale we may now be able to explore the utility of this Trx-1 inhibitor alone or more likely in combination with newly identified cytotoxic or novel agents in reversing resistance and treating patients with r/r DLBCL. This evidence concerns the gene TXN and diffuse large B-cell lymphoma.